Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia

PURPOSE: Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often include minimal residual disease (MRD), leading to relapse and repeated treatments. Rituximab can clear MRD, but long-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Chihara, Dai, Arons, Evgeny, Stetler-Stevenson, Maryalice, Yuan, Constance M., Wang, Hao-Wei, Zhou, Hong, Raffeld, Mark, Xi, Liqiang, Steinberg, Seth M., Feurtado, Julie, James, Lacey, Wilson, Wyndham, Braylan, Raul C., Calvo, Katherine R., Maric, Irina, Dulau-Florea, Alina, Kreitman, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213585/
https://ncbi.nlm.nih.gov/pubmed/32109194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02250
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados